Hot Railroad Companies To Watch In Right Now

Hot Railroad Companies To Watch In Right Now: BioCryst Pharmaceuticals Inc.(BCRX)

BioCryst Pharmaceuticals, Inc., a biotechnology company, designs, optimizes, and develops small-molecule pharmaceuticals that block key enzymes involved in infectious diseases, cancer, and inflammatory diseases. It uses structure-based drug design, which incorporates multiple scientific disciplines, including biology, crystallography, medicinal chemistry, and computer to develop new therapeutic candidates. The company has three novel late-stage compounds in development, which include Peramivir, a neuraminidase inhibitor for the potential treatment of influenza; BCX4208, a purine nucleoside phosphorylase (PNP) inhibitor for gout; and Forodesine, a PNP inhibitor for cutaneous T-cell lymphoma (CTCL) and chronic lymphocytic leukemia (CLL). Peramivir is being developed under a contract from the Biomedical Advanced Research and Development Authority within the United States Department of Health and Human Services. Forodesine has been granted orphan drug status by the FDA for thr ee indications, which include T-cell non-Hodgkin?s lymphoma, including CTCL; CLL and related leukemias, including T-cell prolymphocytic leukemia, adult T-cell leukemia, and hairy cell leukemia; and for treatment of B-ALL. The FDA has also granted fast track status to the development of forodesine for the treatment of relapsed or refractory T-cell leukemia, and special protocol assessment from the FDA for forodesine to conduct a pivotal clinical trial in CTCL with an oral formulation. The company announced the initiation of a Phase 2b study of BCX4208 as add-on therapy in gout patients who have not responded to allopurinol therapy alone. BioCryst Pharmaceuticals utilizes crystallography and structure-based drug design to discover additional compounds and to progress others through pre-clinical and early development to address the unmet medical needs of patients and physicians. The company was founded in 1986 and is headquartered in Durham, No! rth Carolina.

Advisors' Opinion:

• [By Roberto Pedone]

  Another under-$10 name in the bio therapeutic space that's starting to move within range of triggering a major breakout trade is BioCryst Pharmaceuticals (BCRX), which designs, optimizes and develops novel drugs that block key enzymes involved in cancer, viral infections and autoimmune diseases. This stock has been on fire so far in 2013, with shares up a whopping 380%.

  If you take a look at the chart for BioCryst Pharmaceuticals, you'll notice that this stock recently formed a double bottom chart pattern at $6.07 to $6.24 a share. Following that bottom, shares of BCRX are now starting to spike higher right off its 50-day moving average of $6.50 a share. That spike is quickly pushing shares of BCRX within range of triggering a major breakout trade.

  Market players should now look for long-biased trades in BCRX if it manages to break out above some near-term overhead resistance levels at $6.88 to $6.89 a share, and then once it takes out more resistance at $7.56 to its 52-week high at $7.80 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average action of 2.51 million shares. If that breakout triggers soon, then BCRX will set up to enter new 52-week-high territory above $7.80, which is bullish technical price action. Some possible upside targets off that breakout are $10 to $12 a share.

  Traders can look to buy BCRX off weakness to anticipate that breakout and simply use a stop that sits right below those key near-term support levels at $6.24 to $6.07 a share. One can also buy BCRX off strength once it clears those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.

source from Top Penny Stocks For 2015:http://www.seekpennystocks.com/hot-railroad-companies-to-watch-in-right-now.html